Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups

被引:3
|
作者
Fukuda, Tatsuya [1 ,2 ,3 ]
Okamoto, Takahiro [1 ]
Fukaishi, Takahiro [4 ]
Kawakami, Akio [5 ]
Tanaka, Makoto [4 ]
Yamada, Tetsuya [3 ]
Monzen, Koshiro [5 ]
机构
[1] Mirraza Shinjuku Tsurukame Clin, Tokyo, Japan
[2] Tokyo Metropolitan Okubo Hosp, Dept Endocrinol & Metab, Tokyo, Japan
[3] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Mol Endocrinol & Metab, Tokyo, Japan
[4] Koganei Tsurukame Clin, Tokyo, Japan
[5] Shinjuku Tsurukame Clin, Tokyo, Japan
来源
FRONTIERS IN ENDOCRINOLOGY | 2024年 / 15卷
关键词
metabolic dysfunction-associated steatotic liver disease (MASLD); nonalcoholic fatty liver disease (NAFLD); metabolic and alcohol related/associated liver disease (MetALD); alcohol consumption; weight loss; INDEX; ASIA;
D O I
10.3389/fendo.2024.1392280
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction The incidence of steatotic liver disease has increased in recent years. Thus, steatotic liver disease is a major public health issue in Japan. This study investigated the association between weight reduction and the remission of metabolic dysfunction-associated steatotic liver disease (MASLD)/Metabolic and alcohol related/associated liver disease (MetALD) in Japanese individuals undergoing health checkups.Methods This retrospective observational study included 8,707 Japanese patients with MASLD/MetALD who underwent health checkups from May 2015 to March 2023. The participants were monitored for its remission at their subsequent visit. MASLD was diagnosed on abdominal ultrasonography and based on the presence of at least one of five metabolic abnormalities. The impact of body mass index (BMI) reduction on MASLD/MetALD remission was assessed via logistic regression analysis and using receiver operating characteristic curves.Results Logistic regression analysis revealed that weight loss was significantly associated with MASLD/MetALD remission. Other factors including exercise habits and reduced alcohol consumption were significant predictors of MASLD/MetALD remission in the overall cohort and in male patients. The optimal BMI reduction cutoff values for MASLD/MetALD remission were 0.9 kg/m2 and 4.0% decrease in the overall cohort, 0.85 kg/m2 and 3.9% decrease in males, and 1.2 kg/m2 and 4.5% decrease in females. In participants with a BMI of 23 kg/m2, the cutoff values were 0.75 kg/m2 and 2.7% BMI reduction.Discussion Weight reduction plays an important role in both MASLD and MetALD remission among Japanese individuals. That is, targeting specific BMI reduction is effective. This underscores the importance of targeted weight management strategies in preventing and managing MASLD/MetALD in the Japanese population.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] NAD metabolic therapy in metabolic dysfunction-associated steatotic liver disease: Possible roles of gut microbiota
    Lu, Xinyi
    Yang, Rui
    Chen, Yu
    Chen, Daozhen
    ISCIENCE, 2024, 27 (03)
  • [22] Unlocking liver health: Can tackling myosteatosis spark remission in metabolic dysfunction-associated steatotic liver disease?
    Henin, Guillaume
    Loumaye, Audrey
    Deldicque, Louise
    Leclercq, Isabelle A.
    Lanthier, Nicolas
    LIVER INTERNATIONAL, 2024, 44 (08) : 1781 - 1796
  • [23] Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions
    Beygi, Mohammad
    Ahi, Salma
    Zolghadri, Samaneh
    Stanek, Agata
    NUTRIENTS, 2024, 16 (14)
  • [24] Association of liver fibrosis progression with non-liver-related mortality in metabolic dysfunction-associated steatotic liver disease
    Tada, Toshifumi
    Kumada, Takashi
    Toyoda, Hidenori
    Yasuda, Satoshi
    Koshiyama, Yuichi
    Akita, Tomoyuki
    Kodama, Yuzo
    Tanaka, Junko
    HEPATOLOGY RESEARCH, 2025,
  • [25] Visceral Fat and Diabetes: Associations With Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Kumar, Ashish
    Arora, Anil
    Sharma, Praveen
    Jan, Shayesta
    Ara, Ishrat
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2025, 15 (01)
  • [26] Frailty and risk of metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases
    Zhong, Qi
    Zhou, Rui
    Huang, Yi-Ning
    Huang, Rui-Dian
    Li, Fu-Rong
    Chen, Hao-Wen
    Wei, Yan-Fei
    Liu, Kuan
    Cao, Bi-Fei
    Liao, Kai-Yue
    Xu, Zheng-Yun
    Wang, Shi-Ao
    Wu, Xian-Bo
    JOURNAL OF HEPATOLOGY, 2025, 82 (03)
  • [27] Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies
    Bourganou, Maria V.
    Chondrogianni, Maria Eleni
    Kyrou, Ioannis
    Flessa, Christina-Maria
    Chatzigeorgiou, Antonios
    Oikonomou, Evangelos
    Lambadiari, Vaia
    Randeva, Harpal S.
    Kassi, Eva
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (04)
  • [28] Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Elshaer, Amani
    Chascsa, David M. H.
    Lizaola-Mayo, Blanca C.
    LIFE-BASEL, 2024, 14 (07):
  • [29] Evidence summary of lifestyle interventions in adults with metabolic dysfunction-associated steatotic liver disease
    Chen, Mei-jing
    Chen, Ying
    Lin, Jin-qing
    Hu, Rong
    Liu, Dun
    Chen, Jing-yi
    Li, Ka
    Jiang, Xiao-ying
    FRONTIERS IN NUTRITION, 2025, 11
  • [30] Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
    Chan, Wah-Kheong
    Chuah, Kee-Huat
    Rajaram, Ruveena Bhavani
    Lim, Lee-Ling
    Ratnasingam, Jeyakantha
    Vethakkan, Shireene Ratna
    JOURNAL OF OBESITY & METABOLIC SYNDROME, 2023, 32 (03) : 197 - 213